Literature DB >> 8300134

Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13.

R P Baum1, A A Noujaim, A Nanci, V Moebus, A Hertel, A Niesen, B Donnerstag, T Sykes, G Boniface, G Hör.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8300134     DOI： 10.1089/hyb.1993.12.583

Source DB:  PubMed          Journal:  Hybridoma        ISSN： 0272-457X


× No keyword cloud information.
  7 in total

1.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

Review 2.  Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

Authors:  Rachel N Grisham; Jonathan Berek; Jacobus Pfisterer; Paul Sabbatini
Journal:  Immunotherapy       Date:  2011-02       Impact factor: 4.196

3.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

Review 4.  Monoclonal antibodies in gynecological cancer: a critical point of view.

Authors:  Filippo Bellati; Chiara Napoletano; Maria Luisa Gasparri; Valeria Visconti; Ilaria Grazia Zizzari; Ilary Ruscito; Jlenia Caccetta; Aurelia Rughetti; Pierluigi Benedetti-Panici; Marianna Nuti
Journal:  Clin Dev Immunol       Date:  2011-12-26

5.  Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imaging.

Authors:  Sai Kiran Sharma; Melinda Wuest; Monica Wang; Darryl Glubrecht; Bonnie Andrais; Suzanne E Lapi; Frank Wuest
Journal:  EJNMMI Res       Date:  2014-11-12       Impact factor: 3.138

6.  Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma.

Authors:  Jacob L Goldberg; Fariba Navid; Jacqueline A Hank; Amy K Erbe; Victor Santana; Jacek Gan; Fenna de Bie; Amal M Javaid; Anna Hoefges; Michael Merdler; Lakeesha Carmichael; KyungMann Kim; Michael W Bishop; Michael M Meager; Steven D Gillies; Janardan P Pandey; Paul M Sondel
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

Review 7.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Authors:  Mildred Felder; Arvinder Kapur; Jesus Gonzalez-Bosquet; Sachi Horibata; Joseph Heintz; Ralph Albrecht; Lucas Fass; Justanjyot Kaur; Kevin Hu; Hadi Shojaei; Rebecca J Whelan; Manish S Patankar
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.